Compare GIFT & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIFT | CALC |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.0M | 9.7M |
| IPO Year | N/A | 2020 |
| Metric | GIFT | CALC |
|---|---|---|
| Price | $0.97 | $0.99 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 55.4K | ★ 1.0M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | N/A | N/A |
| Revenue This Year | $8.19 | N/A |
| Revenue Next Year | $10.30 | N/A |
| P/E Ratio | ★ N/A | $3.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.46 |
| 52 Week High | $1.40 | $7.20 |
| Indicator | GIFT | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 57.74 |
| Support Level | $0.99 | $0.52 |
| Resistance Level | $1.13 | $1.14 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 64.60 | 69.74 |
Giftify Inc operates in the incentive and rewards industry with a focus on retail, dining, and entertainment experiences, as the owner and operator of digital platforms, CardCash.com, Restaurant.com, and Takeout7.com. CardCash.com is a secondary gift card exchange platform, allowing consumers and retailers to buy and sell gift cards at various scales from several retailers; Restaurant.com is a restaurant-focused digital deals brand, connecting digital consumers and businesses by offering dining, retail, and entertainment deal options at several restaurants and retailers; and Takeout7 is a restaurant technology company offering online ordering solutions and AI-powered digital marketing services. Giftify has one segment, the sale of gift cards and discount certificates to its customers.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.